3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Melanoma
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Glioma
2
Brain Neoplasms
2
Uveal Melanoma
1
Thrombocytosis
1
Sarcoma
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced Thyroid Gland Carcinoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Radiotherapy
4
Carboplatin
4
Trastuzumab
3
Fulvestrant
3
Cyclophosphamide
3
Chemotherapy, Adjuvant
3
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Docetaxel
2
repotrectinib
1
proto-oncogene protein c-fes-fps
1
palbociclib
1
neratinib
1
gallium 68 PSMA-11
1
fluciclovine F-18
1
entrectinib
1
Zolpidem
1
Vorinostat
1
Vinorelbine
1
Venlafaxine Hydrochloride
1
Thiotepa
1
Taxes
1
Tamoxifen
1
Sugars
1
Sampling Studies
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiotherapy, Conformal
1
Radiotherapy, Adjuvant
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Lobular
×
entrectinib
×
Clear all
NCT04551495
2024-12-04
ROSALINE
Jules Bordet Institute
Phase 2
Unknown
65 enrolled